Emerging Therapies and Expert Insights in Systemic Mastocytosis

In the final episode, ‘Emerging Therapies and Expert Insights in Systemic Mastocytosis,’ the expert dermatologist explores the following critical questions:

1. How might emerging targeted therapies, such as bezuclastinib and elenestinib, change the current treatment landscape of SM?
2. Please share any final key takeaways or practice pearls for other clinicians taking care of patients with SM.

Dr. Madigan highlights the evolving treatment landscape by discussing promising clinical trial data for second-generation KIT inhibitors, like bezaclastinib and elenestinib, which offer high selectivity and limited CNS penetration. She reinforces the "practice pearl" that nearly all adults with fixed skin lesions have systemic disease, emphasizing that these lesions are distinct from transient hives and require lifelong vigilance. Dr. Madigan warns that a serum tryptase level below 20 does not rule out systemic mastocytosis, sharing cautionary examples of patients who suffered fragility fractures or catastrophic anaphylaxis after their condition was mischaracterized as skin-limited. Ultimately, she encourages clinicians to partner with Centers of Excellence to ensure patients receive proper staging, specialized education, and access to emerging targeted therapies that can significantly restore their quality of life.

Thank you for watching this Case-Based Peer Perspectives series on systemic mastocytosis. Please subscribe to our newsletter for information on upcoming video series.